Reni Benjamin
Stock Analyst at JMP Securities
(1.53)
# 3,274
Out of 4,876 analysts
194
Total ratings
41.61%
Success rate
-12.11%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Downgrades: Market Perform | n/a | $128.11 | - | 22 | Jun 3, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $14.50 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $7.24 | +203.87% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.74 | +169.91% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.38 | +160.42% | 9 | Mar 31, 2025 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.18 | +323.73% | 7 | Mar 14, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $68.37 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.63 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.02 | +292.16% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.66 | +140.96% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $2.32 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.01 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.42 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.25 | +6,430.61% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $18.16 | -44.93% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $2.81 | +77.94% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $5.67 | +393.83% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $22.69 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $20.60 | +94.17% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.31 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.69 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.79 | +409.36% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.73 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $8.14 | -1.72% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $56.93 | +5.39% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.37 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $237.37 | +32.70% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $91.53 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $238.79 | +10.98% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $2.96 | +474.32% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.26 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.40 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.19 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $36.72 | -67.32% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.49 | - | 1 | Nov 15, 2017 |
Blueprint Medicines
Jun 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $128.11
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $14.50
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $7.24
Upside: +203.87%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.74
Upside: +169.91%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.38
Upside: +160.42%
Allogene Therapeutics
Mar 14, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.18
Upside: +323.73%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $68.37
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.63
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.02
Upside: +292.16%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.66
Upside: +140.96%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $2.32
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.01
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $7.42
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.25
Upside: +6,430.61%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $18.16
Upside: -44.93%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $2.81
Upside: +77.94%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $5.67
Upside: +393.83%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $22.69
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $20.60
Upside: +94.17%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.31
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.69
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.79
Upside: +409.36%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.73
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $8.14
Upside: -1.72%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $56.93
Upside: +5.39%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.37
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $237.37
Upside: +32.70%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $91.53
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $238.79
Upside: +10.98%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $2.96
Upside: +474.32%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.26
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.40
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.19
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $36.72
Upside: -67.32%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $13.49
Upside: -